---
schema_version: "secwatch.filing_event.v1"
accession: "0000929638-25-004243"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:09:13.940576+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents Reports Q3 2025 Revenue of $9.5M, Up 10% YoY, and Provides Business Update

## Summary
- Revenue was $9.5 million for Q3 2025, a 10% increase from $8.6 million in Q3 2024, driven by record distributor sales.
- Amended credit agreement with Avenue Capital Group added $2.5 million in term loans and extended interest-only period to December 31, 2026.
- Workforce reduction of approximately 10% implemented to accelerate path to cash-flow breakeven by Q1 2026, with up to $900,000 in restructuring charges.
- Pre-submission meeting request for DrugSorb-ATR De Novo application submitted to FDA; formal submission expected Q1 2026 with regulatory decision anticipated mid-2026.
- Gross margin improved to 70% from 61% a year ago; operating loss narrowed to $2.9 million from $4.8 million.

## SEC filing metadata
- accession: 0000929638-25-004243
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000092963825004243/0000929638-25-004243-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000092963825004243/a8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000929638-25-004243
- JSON: https://secwatch.observer/filing/0000929638-25-004243.json
- Plain text: https://secwatch.observer/filing/0000929638-25-004243.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.